<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327717</url>
  </required_header>
  <id_info>
    <org_study_id>E2090-AS086-311</org_study_id>
    <nct_id>NCT00327717</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures</brief_title>
  <official_title>A Multicenter, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The objectives of this trial are to evaluate the safety and efficacy of Zonisamide as
      adjunctive therapy in medically refractory patients receiving other antiepileptic drugs
      (AEDs).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Percent Change From Baseline in All Partial Seizure Frequency (Complex Partial Seizures (CP)+ Simple Partial Seizures (SP) + Secondary Generalization Seizures (SGS)) During the Fixed-dose Phase</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>The median percent change in seizure frequency of all partial seizures (CP+SP+SGS) from baseline during the fixed-dose phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Mean Percent Change From Baseline in Complex Partial (CP) Seizure Frequency</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>The Mean Percent Change in seizure frequency of CP from baseline during the fixed-dose phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Percent Change From Baseline in Simple Partial (SP) Seizure Frequency</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>The Mean percent change in seizure frequency of SP from baseline during the fixed-dose phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Percent Change From Baseline in Partial Seizures With Secondary Generalization (SGS)</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>The mean percent change in seizure frequency of SGS from baseline during the fixed-dose phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Responder rate is defined as percentage of participants with &gt;=50% reduction in seizure frequency from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Seizure Free Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean number of seizure free days per 28 day period during fixed dose phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Change in Seizure Free Days</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time to First Seizure (Days)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Mean time to first seizure during fixed dose phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Seizure-free Participants During Fixed-dose Phase</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percentage of seizure-free participants during fixed-dose phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop - Out Rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of Participants who dropped out of the study. In the Study drop-out rate is defined as number of participants.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Partial Seizures</condition>
  <arm_group>
    <arm_group_label>Zonisamide 100 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide</intervention_name>
    <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
    <arm_group_label>Zonisamide 100 mg tablet</arm_group_label>
    <other_name>Zonegran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        According to the International League Against Epilepsy (ILAE) classification of seizure
        type (1981) and international classification of epilepsies and epileptic syndromes (ILAE,
        1989), definite diagnosis of partial seizures (with or without secondary generalized
        seizures) refractory to current anti epilepsy drug (AED) therapy.

        Inclusion criteria:

          1. Adult male or female, 16 to 70 years old;

          2. Classified according to the ILAE classification of seizure type (1981) and
             international classification of epilepsy and epileptic syndromes (ILAE, 1989) into
             partial seizures (with or without secondary generalized seizures);

          3. Based on the retrospective subject diary, at least 4 partial seizures per month ( 4
             weeks ) within 12 weeks prior to entry;

          4. No more than 8 secondary generalized tonic, clonic, or tonic-clonic seizures per month
             within 12 weeks prior to entry;

          5. Antiepileptic therapy including at least 1-2 concomitant AEDs and were on a stable
             dose(s) of the same AEDs for the 3 months prior to enrollment;

          6. Had performed electro encephalogram (EEG) within 6 months prior to entry, and computer
             tomography (CT) or magnetic resonance imaging (MRI) examination to mainly exclude
             space-occupying disease;

          7. Was able to count seizure frequencies;

          8. Women with child bearing potential, were not to be pregnant or nursing, and must have
             agreed to practice during the study a reliable form of contraception (oral
             contraceptive, condom, intrauterine device or diaphragm).

          9. Signed written informed consent and agreed to comply with the protocol.

        Exclusion criteria:

          1. History or evidence of a progressive central nervous system (CNS) disease;

          2. Nonepileptic seizures and pseudoepileptic seizures;

          3. Severe mental retardation or unstable psychical status;

          4. Clinically significant cardiac, hepatic, renal, or hematological disease, uncontrolled
             hypertension (systolic blood pressure (SBP) ≥150 and/or diastolic blood pressure (DBP)
             ≥100mmHg), Symptomatic ischemic heart disease, cerebral infarction or atherosclerosis
             obliterans;

          5. History of malignant neoplastic disease;

          6. Any condition that might interfere the pharmacokinetics (absorption, distribution,
             and/or excretion) of drugs, such as liver or kidney dysfunction, hypoproteinemia;

          7. Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency or history of hemolytic anemia
             or acute intermittent porphyria.

          8. History of kidney stone;

          9. History of alcohol or drug abuse within 2 years;

         10. Sensitivity to sulfonamide medications or history of severe drug allergy;

         11. Administration of monoamine oxidase inhibitor (MAOI), antidepressants or antipsychotic
             a psycho-tropic within 14 days prior to entry;

         12. History of status epileptics in the past years or seizure clusters where individual
             seizures cannot be counted ;

         13. History of zonisamide administration;

         14. History of acetazolamide administration to treat epilepsy within 2 months prior to
             entry;

         15. Joined the clinical trial of other AEDs within 30 days prior to entry;

         16. Pregnant women or women in lactation;

         17. Abnormal clinical laboratory values with clinical significance judged by investigators
             (for example, if abnormal hepatic function is caused by concurrent other AEDs, the
             abnormal value within 2 times of normal could be acceptable);

         18. Inability of subject to return for scheduled visits or to comply with any other aspect
             of the protocol.

         19. Subjects who, in the opinion of the investigator, were poor medical candidates or pose
             any other risk for therapy with an investigational drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Di Hong</last_name>
    <role>Study Director</role>
    <affiliation>Eisai China Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Hua-shan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XiÆan Xijing Hospital</name>
      <address>
        <city>XiÆan</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chengdu Huaxi Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2006</study_first_submitted>
  <study_first_submitted_qc>May 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2006</study_first_posted>
  <results_first_submitted>October 28, 2010</results_first_submitted>
  <results_first_submitted_qc>August 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2014</results_first_posted>
  <last_update_submitted>August 14, 2014</last_update_submitted>
  <last_update_submitted_qc>August 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Partial seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zonisamide 100 mg Tablet</title>
          <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zonisamide 100 mg Tablet</title>
          <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="106"/>
            <count group_id="B3" value="217"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.72" spread="12.18"/>
                    <measurement group_id="B2" value="30.69" spread="11.59"/>
                    <measurement group_id="B3" value="31.73" spread="11.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Percent Change From Baseline in All Partial Seizure Frequency (Complex Partial Seizures (CP)+ Simple Partial Seizures (SP) + Secondary Generalization Seizures (SGS)) During the Fixed-dose Phase</title>
        <description>The median percent change in seizure frequency of all partial seizures (CP+SP+SGS) from baseline during the fixed-dose phase.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide 100 mg Tablet</title>
            <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in All Partial Seizure Frequency (Complex Partial Seizures (CP)+ Simple Partial Seizures (SP) + Secondary Generalization Seizures (SGS)) During the Fixed-dose Phase</title>
          <description>The median percent change in seizure frequency of all partial seizures (CP+SP+SGS) from baseline during the fixed-dose phase.</description>
          <population>Full analysis set (FAS)</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.42" spread="73.83" lower_limit="-100" upper_limit="475"/>
                    <measurement group_id="O2" value="-26.58" spread="157.22" lower_limit="-100" upper_limit="1360.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Percent Change From Baseline in Complex Partial (CP) Seizure Frequency</title>
        <description>The Mean Percent Change in seizure frequency of CP from baseline during the fixed-dose phase.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>FAS population. Complex partial seizure patients</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide 100 mg Tablet</title>
            <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Percent Change From Baseline in Complex Partial (CP) Seizure Frequency</title>
          <description>The Mean Percent Change in seizure frequency of CP from baseline during the fixed-dose phase.</description>
          <population>FAS population. Complex partial seizure patients</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.65" spread="87.28"/>
                    <measurement group_id="O2" value="-25.21" spread="68.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.253</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Percent Change From Baseline in Simple Partial (SP) Seizure Frequency</title>
        <description>The Mean percent change in seizure frequency of SP from baseline during the fixed-dose phase.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>FAS Population. Simple partial seizure patients</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide 100 mg Tablet</title>
            <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Percent Change From Baseline in Simple Partial (SP) Seizure Frequency</title>
          <description>The Mean percent change in seizure frequency of SP from baseline during the fixed-dose phase.</description>
          <population>FAS Population. Simple partial seizure patients</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.14" spread="62.06"/>
                    <measurement group_id="O2" value="56.03" spread="318.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.211</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Percent Change From Baseline in Partial Seizures With Secondary Generalization (SGS)</title>
        <description>The mean percent change in seizure frequency of SGS from baseline during the fixed-dose phase.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>FAS Population. Secondary generalization patients</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide 100 mg Tablet</title>
            <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Percent Change From Baseline in Partial Seizures With Secondary Generalization (SGS)</title>
          <description>The mean percent change in seizure frequency of SGS from baseline during the fixed-dose phase.</description>
          <population>FAS Population. Secondary generalization patients</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.2" spread="54.81"/>
                    <measurement group_id="O2" value="-4.08" spread="178.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.516</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate</title>
        <description>Responder rate is defined as percentage of participants with &gt;=50% reduction in seizure frequency from baseline.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide 100 mg Tablet</title>
            <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate</title>
          <description>Responder rate is defined as percentage of participants with &gt;=50% reduction in seizure frequency from baseline.</description>
          <population>FAS Population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6"/>
                    <measurement group_id="O2" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>X^2 test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Seizure Free Days</title>
        <description>Mean number of seizure free days per 28 day period during fixed dose phase</description>
        <time_frame>12 weeks</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide 100 mg Tablet</title>
            <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Seizure Free Days</title>
          <description>Mean number of seizure free days per 28 day period during fixed dose phase</description>
          <population>FAS Population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.31" spread="6.14"/>
                    <measurement group_id="O2" value="21.43" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <method>X^2 test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Change in Seizure Free Days</title>
        <time_frame>16 weeks</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide 100 mg Tablet</title>
            <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Change in Seizure Free Days</title>
          <population>FAS Population</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.69" spread="21.93"/>
                    <measurement group_id="O2" value="76.52" spread="25.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <method>X^2 test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Time to First Seizure (Days)</title>
        <description>Mean time to first seizure during fixed dose phase</description>
        <time_frame>16 weeks</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide 100 mg Tablet</title>
            <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time to First Seizure (Days)</title>
          <description>Mean time to first seizure during fixed dose phase</description>
          <population>FAS Population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.31" spread="6.14"/>
                    <measurement group_id="O2" value="21.43" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>X^2 test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Seizure-free Participants During Fixed-dose Phase</title>
        <description>Percentage of seizure-free participants during fixed-dose phase</description>
        <time_frame>16 weeks</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide 100 mg Tablet</title>
            <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Seizure-free Participants During Fixed-dose Phase</title>
          <description>Percentage of seizure-free participants during fixed-dose phase</description>
          <population>FAS Population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.678</p_value>
            <method>X^2 test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drop - Out Rate</title>
        <description>Number of Participants who dropped out of the study. In the Study drop-out rate is defined as number of participants.</description>
        <time_frame>16 weeks</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide 100 mg Tablet</title>
            <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
          </group>
        </group_list>
        <measure>
          <title>Drop - Out Rate</title>
          <description>Number of Participants who dropped out of the study. In the Study drop-out rate is defined as number of participants.</description>
          <population>FAS Population</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Placebo group has 2 fewer subjects - consent withdrawn 1 and lost to follow up 1.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zonisamide 100 mg Tablet</title>
          <description>Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients in placebo group were titrated with placebo in the same way as in zonisamide group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="120"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Takao Ishii, Asia regulatory affairs</name_or_title>
      <organization>Eisai Co., Ltd.</organization>
      <phone>81-3-3817-3914</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

